Tersan’s advanced data analytics, using its KEM® decision support platform, will help ValiSeek boost success outlook.
Tersan® Pharma, a leading digital health Company focused on developing advanced personalized therapeutic decision support systems and a provider of decision support tools and services to accelerate drug development, announces today that it has won a significant contract of a fee-for-service collaboration with ValiSeek, a joint venture of ValiRx Plc (AIM: VAL).
Under the terms of the collaboration, Tersan® will deploy its KEM® (Knowledge Extraction and Management) decision support platform to carry out systematic analysis of VAL401 Phase II clinical data in the treatment of patients with locally advanced or metastatic Non-small Cell Lung Cancer, in order to maximize the probability of successful further development of this drug. Financial terms were not disclosed.